Helena Biosciences has joined forces with Ghent University’s Vlaams Institute voor Biotechnologie (VIB), a life sciences research institute in Flanders, Belgium, to commercialize the Glyco Liver Profile, a new blood test for chronic liver disease (CLD). Developed by researchers at VIB, this noninvasive and automated assay will run on Helena’s V8 Nexus Capillary Electrophoresis analyzer. It examines the glycome of serum proteins to diagnose and monitor CLD ranging from liver inflammation to early and late stage fibrosis and early cirrhosis. It also predicts a patient’s likelihood of developing hepatocellular carcinoma (HCC) within the next 5 years.